NCT07469956 2026-03-13
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
60 trialsNCT05494580 2026-03-10
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT06719700 2026-03-03
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07436741 2026-02-27
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
NCT07272512 2025-12-19
ZSPAC-17
Shanghai Zhongshan Hospital
Phase 4 Recruiting
NCT05472948 2025-12-17
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07279532 2025-12-12
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT05077384 2025-09-16
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
Phase 1/2 Completed
NCT05481476 2025-09-04
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04579679 2025-07-25
Open-Label Surufatinib in European Patients With NET
Hutchmed
Phase 2 Terminated
NCT07086456 2025-07-25
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT05481463 2025-05-28
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sun Yat-sen University
Phase 2 Completed
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT05165407 2025-03-14
NESSIE
Peking University
Phase 2 Recruiting
NCT05218889 2024-12-31
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05652283 2024-11-27
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 2 Active not recruiting
NCT06437353 2024-11-27
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT06239532 2024-11-21
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT04922658 2024-07-31
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Unknown
NCT06531291 2024-07-31
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
Phase 2 Not yet recruiting
NCT05832892 2024-06-14
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT05093322 2024-06-07
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT06447636 2024-06-07
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06414915 2024-05-16
Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation
National Cancer Center, China
Phase 2 Not yet recruiting
NCT06375642 2024-04-19
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05926492 2024-04-17
A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06255262 2024-02-13
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
China Medical University, China
Phase 1/2 Unknown
NCT06158516 2023-12-06
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Changhai Hospital
Phase 2 Not yet recruiting
NCT06134193 2023-11-18
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05988372 2023-11-01
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05989425 2023-08-14
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Fudan University
Phase 2 Recruiting
NCT04653480 2023-07-17
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Zhejiang University
Phase 2 Unknown
NCT05882630 2023-05-31
Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 1/2 Not yet recruiting
NCT05106777 2023-04-12
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT05746728 2023-04-06
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
Tongji Hospital
Phase 1/2 Unknown
NCT02588170 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT02589821 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT05747729 2023-02-28
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05627427 2022-11-25
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04996771 2022-11-14
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT05003037 2022-11-04
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05590572 2022-10-21
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT05186545 2022-09-02
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05171439 2022-04-14
Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05282433 2022-03-16
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Zhongnan Hospital
Phase 2 Unknown
NCT05056116 2021-12-27
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase NA Unknown
NCT04764006 2021-11-04
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
Fujian Cancer Hospital
Phase 2 Unknown
NCT05030246 2021-09-01
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
Peking University
Phase 2 Unknown